precision-biotech-therapeutics theme · 72 dossiers

Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs SPY003 IL-23 Part A (guided mid-2026, overdue)…

USRC-sponsored VOICE outcomes trial (2026-06-30) stopped early for success Vafseo cut dialysis hospitalizations vs ESAs with neutral mortality, a hard-data adoption catalyst for this ~$1.40 renal micro-cap. But price sits near its 52-week…

Legacy-generics-to-specialty re-rate still accelerating on CREXONT (Phase 4 data + EU CHMP nod 2026-06-29), romidepsin CGT exclusivity and the $1.1B Kashiv biosimilar build but price ran parabolic to 52-week highs above the $15.50…

Pure-play Jemperli/imsidolimab royalty stub since the April spin-off; the entire equity now hinges on the 2026-07-14–17 Delaware Chancery trial on royalty reversion and rate preservation now 1–3 trading days out. A binary legal verdict,…

Precision-psychiatry re-rate that has already run ~10x off a $2.50 low to near its $28.44 high; funded through 2029 on the March $120M PIPE, but every binary readout (ALTO-300, ALTO-100, ALTO-207 in TRD) sits in 2027 the tape near highs is…

Between-catalyst psychedelic leader jolted by a 2026-07-06 volume spike on an unconfirmed M&A-blog takeout rumor, stacked on Russell 2000/3000 inclusion (effective 2026-06-29) and a Canaccord PT bump to $17 (2026-07-07). The one hard…

Broken-growth AID-pump name in a pre-earnings holding pattern: the ~2026-07-28 Q2 print is the binary that decides whether new patient starts re-accelerate or post a second straight sequential decline. June's ~$14 relief bounce off the…

Left-for-dead pivot re-rated ~6x off $4: oral NLRP3 inhibitor BGE-102 reframes BIOA as a "statin-for-inflammation" CV play after median 86% hsCRP cuts in Phase 1. QUELL-CV Phase 2 topline (2H 2026) is the binary. Now grinding fresh 52-week…

CAN-2409 narrative re-armed on the 2026-06-30 AURORA Phase 3 launch in post-ICI NSCLC a second pivotal program in a far larger indication plus an ex-AstraZeneca lung CCO hire; the stock cleared the old $9.27 high to an $11.36 peak, then…

Analyst-confirmed profitability inflection (Q1'26: adj-EBITDA +$4.0M, +$6.2M op cash, +24% product rev) in a 25-year blood-safety grinder but the 2.7x off the lows is largely spent and price is pinned at 52-week highs (~$3.19 vs $3.21).…

Resolved special situation: Lilly closed its $38.00 cash plus up-to-$9.00 non-transferable CVR scheme on 2026-06-24 after the 2026-06-22 High Court sanction; last Nasdaq ADS trade was 2026-06-23 and shares have delisted and are…

Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry…

Deal-arb thesis is now spent: the $100M Apotex asset sale closed 2026-07-01 after a 99.84% shareholder vote on 2026-06-24, so the dated binary that drove the ~3.2x off $1.85 to a $7.36 high is consumed. What remains is a cash-rich clinical…

Momentum story is dead it crystallized into Vertex's $85.00/share all-cash takeout (announced 2026-07-06, ~$10B). Shares gapped to $83.53 (+99%) and now trade as a merger-arb spread capped at $85, with ~$40 of air below on a deal-break. No…

CGT cold-chain picks-and-shovels; the 2026 re-rate has matured. Consensus PT drifted to $15.11 (now just below the ~$15.26 spot), the rating softened to Moderate Buy with two holds added, and insiders distributed into the early-June $16.73…

ARCHIMED take-private cleared its last binary: the 2026-07-08 vote adopted the deal (135.3M for vs 22.8M against), and with HSR and German antitrust already done only the mechanical Q3 close and Nasdaq delisting remain. Stock is pinned at…

Q1 beat-and-raise (adj EPS $0.14 vs $0.09, FY26 guide lifted above $120M, 2026-05-14) confirmed the specialty-pharma rollup, but the story stopped accelerating in mid-May and now drifts through an empty window into the ~August Q2 print the…

CRO margin-turnaround already re-rated FTRE ~4x off its 2025 low; the Q1 beat that drove it is spent and price sits ~9% under the $18.67 52-week high, above most analyst targets. Fresh positive drift (Zacks Strong-Buy 7/7 on +31% estimate…

Post-dilution CNS microcap that melted up on a social-velocity spike into a blowoff RSI in the mid-90s, then priced a 10.3M-share secondary at $4.85 into the strength. The only underwritable event APPROACH Phase 3 for HLP003 in adjunctive…

GLP-1 reaccel is a promise until the ~2026-08-10 Q2 print the first proof of the +25-28% guide off a +4% Q1 trough. Sell-side has now chased above spot (Canaccord $40, Barclays $39, BofA $37), so upgrade fuel is largely spent, CVS entering…

Commercial ophthalmology special-situation trading on one number: does the guided H2 ramp print. June–July portfolio launches (VERKAZIA, BYOOVIZ) keep sentiment alive, but the binary is the ~Aug 10 Q2 report $71–81M guide vs $44.2M Q1. A…

Precision-oncology name digesting a $300M raise at $27.00 (priced 2026-06-09); analysts cut targets 2026-07-07 (RBC $48, Truist $63) while staying bullish. Darovasertib uveal-melanoma registrational path is the embedded option, but the…

Near-term regulatory binary resolved favorably FDA accepted the ozekibart chondrosarcoma BLA on 2026-06-15 (PDUFA 2027-04-14) but that docketed the defining decision ~9 months out, dropping the name into an extended catalyst vacuum.…

Re-rating leg is spent: stock 6x'd off $0.56 to a $5.78 high on a 2026 AbbVie pricing restructure that drove Linzess net sales +97% YoY, now faded to ~$3.52 mid-range. June 15 note repaid on schedule; the only undated upside left is a…

JADE101's best-in-class Phase 1 binary fired clean (2026-06-01, ~70% IgA reduction, q12w dosing) and the dilutive $150M raise at $15 is now absorbed the stock re-based +31% off the low back above the ~$18 shelf (~$21.68) and drew a UBS Buy…

The Chiesi takeout is done: the tender expired with ~77.8% of shares in (43,152,532 sh), the second-step merger went effective 2026-06-11 at $27.00/share cash, and KALV ceased trading on Nasdaq before the open the same day. No US-listed…

Pension-reversion fat pitch already fired (completed Dec 2 2025; net-cash, $337M FY25 cash) and the re-rate peaked at $14.87 on May 4 before a ~34% correction into a $9.4–9.8 range. What's left is an early, unsigned battery-electrode and…

In-vivo CAR-T re-rate has resolved into digestion: EHA full data (6/13) confirmed LB2501's 100% ORR and durable persistence, but the 6/17 $226M raise at $29.35 capped the move and the stock now sits at the offering price. Maturing…

Parabolic clinical-stage endocrine re-rating: once-weekly canvuparatide's 1-yr Phase 2 OLE (57% responders, 12 Jun) plus a cleared End-of-Phase-2 FDA path drove the stock +580% YTD into all-time highs, with obesity prodrug optionality…

Flu-vaccine approval story confirmed by an early-July sell-side PT cluster-raise (Piper $77, RBC $45, MS $39, BofA $34→$38), but the clean +30% momentum leg already ran into the June 18 9-0 advisory vote. The Aug 5 mRNA-1010 PDUFA is now…

Post-COVID survivor re-rate has gone parabolic: +31% in three weeks to a fresh 52-week high of $6.22 (June 26), clearing every analyst target on the May 7 Q1 beat-raise, June 2 refi and June 15 TriLink GMP enzyme facility. The move is…

Oncology-dx turnaround ACCELERATING NGS +26%, RaDaR ST attach building, guide raised and price broke out above the old $13.74 high into blue-sky mid-teens, past the $15.06 consensus PT. The June $275M convert refinances 2028 debt and caps…

Feb-2026 REZOLVE-AD maintenance pop to $109 has fully round-tripped; NKTR has stabilized near $62 — but the next true binary (ZENITH-AD Phase 3 AD readout) is mid-2028, so there is no accelerating leg to buy. The mechanism is de-risked yet…

TRIDENT, the binary the 2026 markup was built on, missed its overall-survival endpoint (topline 2026-06-18); shares fell ~20% to ~$14.50 and sit near $15.43. The miss was contained (it tested timing, not the core GBM indication), but the…

The EU upside binary broke: CHMP issued a negative opinion on YARTEMLEA in TA-TMA (2026-06-26), gapping OMER ~20% to ~$8.70 and slicing the $8.50 base. What remains is a US-only orphan launch (Q1 net $9.9M, Q2 consensus ~$11.6M) plus a…

Fertility-benefits turnaround re-rate is MATURING but still bid stock grinding $25→$27 toward the $28.75 52-wk high while Street targets keep rising (Truist $33 on 6/22, avg ~$30). No binary until the 2026-07-30 Q2 print; constructive but…

Sell-side discovery leg has played out fast from one Canaccord Buy ($32, 2026-06-04) to a 3-broker Strong Buy cluster (Mizuho/Oppenheimer $30) plus S&P Healthcare Equipment index inclusion (2026-06-12), driving fresh highs near $30. Price…

RAP-219 platform validated at AAN; the stock has round-tripped the post-print dip back to ~$40, within ~5% of its $42.27 52-wk high, on a fresh sell-side coverage wave (Leerink Outperform $52, 6/24; avg PT ~$56.64). But the next real…

Special-situations reverse merger, not a momentum trade: 2026-06-01 Avenzo deal + $215M PIPE; combined co trades AVZO, closes Q4 2026. Stock holds near 52-wk highs (~$15.71, 2026-06-25) as the market credits stub+CVR optionality, but…

Oral-GPCR platform narrative has matured from accelerating to extended after a ~3.5x run to an all-time high of $37.99; the ENDO 2026 visibility event came and went and the tape now sits in a catalyst vacuum, with the first real binary…

April momentum round-trip is complete; SGMT base-builds near $7.06, ~18% above the $6.00 Series A offering floor that keeps holding. Dermatology pivot (China acne NDA accepted, US acne IND filing targeted mid-2026) is the next leg, but the…

MEMS timing picks-and-shovels for AI datacenters: Q1 (~May 7) confirmed the re-rate datacenter revenue +158% YoY to ~67% of sales and the Feb-4 Renesas timing deal adds ~$300M of AI-comms revenue. But the stock has cooled ~11% from its…

Squeeze + buyout speculation has overtaken the pre-binary run-up: SLS ran ~$9→$12+ in late June on record ~33%-of-float short interest and change-of-control severance amendments, not clinical data. The Phase 3 REGAL OS readout (78/80…

Single-asset ivonescimab story whose momentum leg has broken: after the Apr-30 HARMONi-3 squamous interim PFS miss and a sold-the-news ASCO, a $500M raise was pulled Jun 10 and the Q1 10-Q flagged going-concern doubt. Shares lost $17 to…

The single event the name was priced around a July no-prior-auth formulary add for neffy came and went with no coverage win (2026-06-25 update). ARS pivoted to opex cuts ($248M guide) to defend 2027 breakeven as the stock sank and Leerink…

Single-asset binary: equity re-minted around STRO-004 (DAR-8 Tissue Factor ADC) after lead luvelta was shelved despite a 32% ORR. Stock bounced from ~$25 to ~$30 on a stacking analyst cluster (Truist $50, 6/11), but it is drifting into an…

Haduvio's IPF-cough story re-accelerated in mid-June: TRVI broke past its $16.12 prior high to ~$18 (June 27) on the FDA-aligned Phase 3 launch (Q2 2026 start, 54mg BID dose locked) plus BIO/ERS conference visibility. The leg runs on…

The Novo-validated GLP-1 muscle-preservation squeeze has fully unwound: VERU round-tripped from a $4.23 close (06-04) to ~$2.88 (06-26), losing the $3.00 warrant strike and pushing RSI from 87.85 to ~51. Catalyst spent, warrants back out…

Last large independent obesity asset and standing M&A target, but VK2735's VANQUISH pivotal topline isn't until 2027 a catalyst vacuum into a maturing, crowded GLP-1 theme, bridged only by a secondary 3Q26 maintenance-dose readout. Stock…

Busted-growth genomics name recovering off the −49% May guide-cut crash ($170→$32); sell-side ratcheting targets back up (Guggenheim $74 Jun 29, Piper $63 Jun 23), but the ~early-Aug Q2 ARR print vs the ~$3,300 baseline is the binary. A…

First annual same-store-sales decline in 22 years (Q1 2026 domestic SSS -8.7%) broke the compounder narrative; a ~50% relief bounce off the $116 low now runs into the July 29 Q2 print the binary on the guided H2 return to positive comps.…

X-TOLE2 Phase 3 win (2026-03-09, placebo-adjusted -42.7%, p≈6e-12) already de-risked azetukalner and re-rated XENE from the $40s to ~$71; the story is now maturing and range-bound into a procedural Q3 2026 NDA, with the next true binary…

Delisting binary resolved to the survive side: EGM passed 2026-06-29, Psyga psilocybin reverse-merger closed 2026-06-30, delinquent 20-F filed, Nasdaq listing held. ADS popped ~+90% intraday to ~$2.70 (~$6.4M cap). Now an illiquid…

IL-17/BAFF bispecific (tibulizumab) ran on a 2026-06-29 enrollment beat in HS and SSc, but that's execution de-risking, not efficacy the real binary is Q4 2026 TibuSHIELD topline. The RSI mid-80s spike faded ~8% into July with no hard…